In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.

Mitch Dowsett(Royal Marsden NHS Foundation Trust), Ian E. Smith(Royal Bournemouth Hospital), Stephen Johnston(Royal Marsden NHS Foundation Trust), Alison Jones(University of Auckland), Patrick Trunet, Stephen C. Jacobs

PubMed

December 1, 1995

Cited by 239

Related Papers

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

|The Lancet|2007|1.5k

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

|JAMA Oncology|2019|983

Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study

|Journal of Clinical Oncology|2009|850

Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials

|BMC Cancer|2010|755

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer

|npj Breast Cancer|2019|673